These molecules selectively inhibit the binding of MEN1 to KMT2Ar, resulting particularly effectively in the treatment of KMT2Ar and other AL subtypes where MEN1 is critical and providing significant clinical benefits for R/R patients with AL, for which limited therapy options exist [1,2,3,34,93,94,95,96]. This evidence concerns the gene MEN1 and axial length measurement.